Viatris Quiet On Generics As Clock Ticks On Value-Add Copaxone Opportunity
2024 Could Heat Up For Firm, With Multiple Big-Ticket Launches And Wegovy Challenge
Executive Summary
Generics Bulletin reviews Viatris’ 2023 financial year, and its prospects ahead of a busy 2024.